(Q48219213)

9 February 2018

title

Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release (English)

1 reference

9 February 2018

1 reference

3

1 reference

9 February 2018

author name string

Karashima T

series ordinal

1

1 reference

9 February 2018

Cai RZ

series ordinal

2

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 August 1987

1 reference

9 February 2018

published in

Life Sciences

1 reference

9 February 2018

volume

41

1 reference

9 February 2018

issue

8

1 reference

9 February 2018

page(s)

1011-1019

1 reference

9 February 2018

Inhibiting effect of somatostatin on growth hormone release induced by isoprenaline or chlorpromazine in rats

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

A super active cyclic hexapeptide analog of somatostatin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Somatostatin: analogs with selected biological activities

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Effect of a long acting glucagon selective somatostatin analogue on plasma glucose, insulin and glucagon levels in the anaesthetized rat during arginine infusion

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Inhibition by six somatostatin analogs of plasma growth hormone levels stimulated by thiamylal and morphine in the rat.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

The diabetogenic action of somatostatin in healthy subjects and in maturity onset diabetics

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Metabolic effects of somatostatin in maturity-onset diabetes.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0024-3205(87)90690-4

Identifiers

DOI

10.1016/0024-3205(87)90690-4

1 reference

9 February 2018

1 reference

9 February 2018